Please assess the completion status of the following clinical trial:

Trial Title: Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* premenopausal women ≥ 18 years~* diagnosis of PCOS based on the recent 2006 Androgen Excess Society criteria (modified from Rotterdam 2003)~* waist circumference \>88 cm~* fasting TG 2.0 - 5.0 mmol/L~* stable on any type of oral contraceptive for a minimum of 3-months~Exclusion Criteria:~* known contraindications for MRI~* pregnancy, lactation, desire to become pregnant~* participation in another clinical trial~* fasting TF level ≥ 5.0 mmol/L~* AST or ALT \> 2.5 times upper limit of normal (ULN)~* creatinine kinase (CK) \> 6x ULN~* creatinine \> 115 μmol/L~* fasting glucose ≥ 7.0 mmol/L and/or 2h glucose post oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L or personal history of DM2~* personal history of renal disease, liver disease (except NAFLD), or heart disease~* body mass index (BMI) \< 18 or \> 40 kg/m²~* increased alcohol use (\>9 standard drinks per week \[standard drink = 12oz beer, 5oz wine, or 1.5oz spirits\]) or drug use~* use of other hormonal contraception, growth hormone, glucocorticoids, anti-diabetic/anti-dyslipidemia medications, or anabolic steroids.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): fenofibrate 200mg/daily for 6 months
- 2 (Type: PLACEBO_COMPARATOR): Placebo match for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).